0000000000761775

AUTHOR

Sebastian Kobold

showing 1 related works from this author

Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients.

2010

Up to 10% of germ cell tumor patients require salvage high-dose chemotherapy with stem cell support, achieving cure rates in the range of 10-60%. Stem cell mobilization may be difficult in these patients because of multiple lines of treatment known to seriously hamper stem cell recovery. Plerixafor significantly enhances the success of the CD34+ cell harvest, even in cases where prior mobilization attempts have failed. Six germ cell tumor patients provided informed consent and were included in the compassionate use program. All patients were heavily pretreated, with a median of 3.5 prior lines of therapy. All failed prior mobilization with G-CSF in combination with chemotherapy. Five patien…

OncologyAdultCompassionate Use TrialsMalemedicine.medical_specialtyBenzylaminesPlatelet Engraftmentmedicine.medical_treatmentCD34Hematopoietic stem cell transplantationCyclamsYoung AdultTesticular NeoplasmsHeterocyclic CompoundsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansUltrasonographyTransplantationChemotherapyMobilizationbusiness.industryPlerixaforHematopoietic Stem Cell TransplantationHematologyMiddle AgedNeoplasms Germ Cell and EmbryonalCombined Modality TherapyHematopoietic Stem Cell MobilizationSurgerySeminomamedicine.anatomical_structureStem cellbusinessGerm cellmedicine.drugBone marrow transplantation
researchProduct